Table of Contents
- About NMS-03592088
- Conditions Treated
- Study Design
- Drug Administration
- Study Outcomes
- Safety Assessment
- Efficacy Measures
About NMS-03592088
NMS-03592088 is a new drug being studied for its potential in treating certain types of blood cancers. It is classified as an inhibitor, specifically targeting three important proteins in cancer cells: FLT3, KIT, and CSF1R[1]. These proteins are often involved in the growth and survival of cancer cells, so blocking them may help to slow down or stop the progression of the disease.
Conditions Treated
The drug is being investigated for two main conditions:
- Acute Myeloid Leukemia (AML): This is a type of cancer that affects the blood and bone marrow, causing rapid growth of abnormal white blood cells.
- Chronic Myelomonocytic Leukemia (CMML): This is a rare blood cancer that affects blood-forming cells in the bone marrow, leading to an increase in a type of white blood cell called monocytes.
The study focuses on patients with relapsed or refractory forms of these diseases, which means their cancer has either returned after treatment or has not responded well to previous treatments[1].
Study Design
The research on NMS-03592088 is being conducted in two parts[1]:
- Phase I: This initial phase includes patients with both AML and CMML. It aims to determine the safety, tolerability, and the best dose of the drug for further testing.
- Phase II: This phase is currently only being conducted in the European Union and focuses on AML patients with a specific genetic mutation called FLT3. It includes two groups:
- Patients who have not responded well to standard treatments, including drugs called venetoclax and gilteritinib.
- Patients who have not responded well to standard care treatments.
Drug Administration
NMS-03592088 is given orally, which means patients can take it by mouth[1]. This method of administration is often more convenient for patients compared to drugs that need to be injected or given intravenously.
Study Outcomes
The researchers are looking at several important outcomes to determine how well NMS-03592088 works and how safe it is[1]:
- Safety: They’re monitoring for any side effects or toxicities, especially in the first cycle of treatment.
- Effectiveness: They’re measuring how well the drug works by looking at remission rates (how many patients show no signs of cancer after treatment) and survival rates.
- Drug behavior in the body: They’re studying how the drug is processed by the body, including how quickly it reaches its maximum concentration in the blood and how long it stays in the system.
Safety Assessment
The safety of NMS-03592088 is being carefully monitored throughout the study[1]. Researchers are tracking any adverse events (side effects) that occur, including any abnormalities found during medical tests such as laboratory tests, vital signs checks, and electrocardiograms (heart tests). This monitoring continues from the time a patient signs the informed consent until 28 days after their last dose of the study drug.
Efficacy Measures
To determine how well NMS-03592088 works, the researchers are looking at several measures[1]:
- Response rates: This includes complete remission (no detectable cancer), partial remission (significant reduction in cancer), and overall response rate.
- Survival rates: They’re measuring overall survival (how long patients live after starting treatment) and event-free survival (how long patients live without their disease getting worse or other significant events).
- Duration of response: This measures how long the positive effects of the treatment last.
- Transfusion independence: They’re checking if patients who previously needed regular blood transfusions no longer need them after treatment.
These measures will help determine if NMS-03592088 is an effective treatment option for patients with AML and CMML, particularly those who have not responded well to other treatments.
